• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估效用分数的差异:四种广泛使用的基于偏好的工具的比较。

Assessing differences in utility scores: a comparison of four widely used preference-based instruments.

作者信息

Wee Hwee-Lin, Machin David, Loke Wai-Chiong, Li Shu-Chuen, Cheung Yin-Bun, Luo Nan, Feeny David, Fong Kok-Yong, Thumboo Julian

机构信息

Singapore General Hospital, Singapore.

出版信息

Value Health. 2007 Jul-Aug;10(4):256-65. doi: 10.1111/j.1524-4733.2007.00174.x.

DOI:10.1111/j.1524-4733.2007.00174.x
PMID:17645680
Abstract

OBJECTIVES

To characterize the differences in utility scores (dUTY) among four commonly used preference-based Health-Related Quality of Life instruments, to evaluate the potential impact of these differences on cost-utility analyses (CUA), and to determine if sociodemographic/clinical factors influenced the magnitude of these differences.

METHODS

Consenting adult Chinese, Malay and Indian subjects in Singapore were interviewed using Singapore English, Chinese, Malay or Tamil versions of the EQ-5D, Health Utilities Index Mark 2 (HUI2) and Mark 3 (HUI3), and SF-6D. Agreement between instruments was assessed using Bland-Altman (BA) plots. Changes in incremental cost-utility ratio (ICUR) from dUTY were investigated using eight hypothetical decision trees. The influence of sociodemographic/clinical factors on dUTY between instrument pairs was studied using multiple linear regression (MLR) models for English-speaking subjects (circumventing structural zero issues).

RESULTS

In 667 subjects (median age 48 years, 59% female), median utility scores ranged from 0.80 (95% confidence interval [CI] 0.80, 0.85) for the EQ-5D to 0.89 (95% CI 0.88, 0.89) for the SF-6D. BA plots: Mean differences (95% CI) exceeded the clinically important difference (CID) of 0.04 for four of six pairwise comparisons, with the exception of the HUI2/EQ-5D (0.03, CI: 0.02, 0.04) and SF-6D/HUI2 (0.02, CI: 0.006, 0.02). Decision trees: The ICER ranged from $94,661/QALY (quality-adjusted life-year; 6.3% difference from base case) to 100,693 dollars/QALY (0.3% difference from base case). MLR: Chronic medical conditions, marital status, and Family Functioning Measures scores significantly (P-value < 0.05) influenced dUTY for several instrument pairs.

CONCLUSION

Although CIDs in utility measurements were present for different preference-based instruments, the impact of these differences on CUA appeared relatively minor. Chronic medical conditions, marital status, and family functioning influenced the magnitude of these differences.

摘要

目的

描述四种常用的基于偏好的健康相关生活质量工具在效用得分(dUTY)上的差异,评估这些差异对成本效用分析(CUA)的潜在影响,并确定社会人口统计学/临床因素是否会影响这些差异的大小。

方法

使用新加坡英语、中文、马来语或泰米尔语版本的EQ-5D、健康效用指数Mark 2(HUI2)、Mark 3(HUI3)和SF-6D,对新加坡同意参与的成年华裔、马来裔和印度裔受试者进行访谈。使用Bland-Altman(BA)图评估工具之间的一致性。使用八个假设决策树研究dUTY导致的增量成本效用比(ICUR)的变化。使用多元线性回归(MLR)模型研究社会人口统计学/临床因素对工具对之间dUTY的影响(避免结构零问题)。

结果

在667名受试者(中位年龄48岁,59%为女性)中,中位效用得分范围从EQ-5D的0.80(95%置信区间[CI]0.80,0.85)到SF-6D的0.89(95%CI 0.88,0.89)。BA图:六个两两比较中有四个的平均差异(95%CI)超过了0.04的临床重要差异(CID),HUI2/EQ-5D(0.03,CI:0.02,0.04)和SF-6D/HUI2(0.02,CI:0.006,0.02)除外。决策树:ICER范围从94,661美元/QALY(质量调整生命年;与基础情况相差6.3%)到100,693美元/QALY(与基础情况相差0.3%)。MLR:慢性疾病、婚姻状况和家庭功能测量得分对几个工具对的dUTY有显著影响(P值<0.05)。

结论

虽然不同的基于偏好工具在效用测量中存在CID,但这些差异对CUA的影响似乎相对较小。慢性疾病、婚姻状况和家庭功能影响了这些差异的大小。

相似文献

1
Assessing differences in utility scores: a comparison of four widely used preference-based instruments.评估效用分数的差异:四种广泛使用的基于偏好的工具的比较。
Value Health. 2007 Jul-Aug;10(4):256-65. doi: 10.1111/j.1524-4733.2007.00174.x.
2
A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.类风湿关节炎患者使用 EQ-5D 和 SF-6D 偏好型通用量表进行效用测量的比较。
Clin Exp Rheumatol. 2011 Jul-Aug;29(4):661-71. Epub 2011 Aug 31.
3
Comparison of the EuroQol and short form 6D in Singapore multiethnic Asian knee osteoarthritis patients scheduled for total knee replacement.新加坡计划进行全膝关节置换术的多民族亚洲膝骨关节炎患者中欧洲五维健康量表与简版6D量表的比较
Arthritis Rheum. 2007 Aug 15;57(6):1043-9. doi: 10.1002/art.22883.
4
A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service.骨折联络服务就诊的荷兰骨折患者中 EQ-5D-5L 与 SF-6D 的头对头比较。
J Med Econ. 2022 Jan-Dec;25(1):829-839. doi: 10.1080/13696998.2022.2087409.
5
A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis.类风湿关节炎中通用间接效用测量方法(健康效用指数2、健康效用指数3、SF-6D和欧洲五维度健康量表)与疾病特异性工具(类风湿关节炎生活质量量表和健康评估问卷)的比较。
Soc Sci Med. 2005 Apr;60(7):1571-82. doi: 10.1016/j.socscimed.2004.08.034.
6
Interchangeability of the EQ-5D and the SF-6D, and comparison of their psychometric properties in a spinal postoperative Spanish population.EQ-5D 与 SF-6D 的可互换性,以及它们在西班牙脊柱术后人群中的心理测量特性比较。
Eur J Health Econ. 2020 Jun;21(4):649-662. doi: 10.1007/s10198-020-01161-4. Epub 2020 Feb 17.
7
Comparison of EuroQol-5D and short form-6D utility scores in multiethnic Asian patients with psoriatic arthritis: a cross-sectional study.多民族亚洲银屑病关节炎患者的 EuroQol-5D 和简短形式-6D 效用评分比较:一项横断面研究。
J Rheumatol. 2013 Jun;40(6):859-65. doi: 10.3899/jrheum.120782. Epub 2013 Mar 15.
8
Validation and comparison of EuroQoL-5 dimension (EQ-5D) and Short Form-6 dimension (SF-6D) among stable angina patients.稳定型心绞痛患者中欧洲五维度健康量表(EQ - 5D)与简短健康调查简表6维度(SF - 6D)的验证与比较
Health Qual Life Outcomes. 2014 Oct 25;12:156. doi: 10.1186/s12955-014-0156-6.
9
Comparison of the EQ-5D 3L and the SF-6D (SF-36) contemporaneous utility scores in patients with chronic kidney disease in Sri Lanka: a cross-sectional survey.斯里兰卡慢性肾脏病患者 EQ-5D 3L 与 SF-6D(SF-36)同期效用评分比较:一项横断面调查。
BMJ Open. 2019 Feb 15;9(2):e024854. doi: 10.1136/bmjopen-2018-024854.
10
Validation and comparison of EuroQol and short form 6D in chronic prostatitis patients.慢性前列腺炎患者的 EuroQol 和简短形式 6D 的验证和比较。
Value Health. 2010 Aug;13(5):649-56. doi: 10.1111/j.1524-4733.2010.00728.x. Epub 2010 Apr 15.

引用本文的文献

1
Cost-effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain.西妥昔单抗联合放疗与单纯放疗治疗西班牙局部晚期头颈癌的成本效益
J Comp Eff Res. 2025 Feb;14(2):e240116. doi: 10.57264/cer-2024-0116. Epub 2025 Jan 10.
2
Comparison of EQ-5D-Y-3L Utility Scores Using Nine Country-Specific Value Sets in Chinese Adolescents.在中国青少年中使用九种特定国家价值集比较EQ-5D-Y-3L效用评分
Pharmacoeconomics. 2025 Feb;43(2):209-221. doi: 10.1007/s40273-024-01451-2. Epub 2024 Nov 12.
3
Cost-effectiveness of cladribine tablets and dimethyl fumarate in the treatment of relapsing remitting multiple sclerosis in Spain.
在西班牙,克拉屈滨片和富马酸二甲酯治疗复发缓解型多发性硬化症的成本效益分析。
J Comp Eff Res. 2023 Feb;12(2):e220193. doi: 10.2217/cer-2022-0193. Epub 2023 Jan 27.
4
Health state utility values measured using the EuroQol 5-dimensions questionnaire in adults with chronic hepatitis C: a systematic literature review and meta-analysis.采用欧洲五维健康量表在慢性丙型肝炎成人中测量健康状态效用值:系统文献回顾和荟萃分析。
Qual Life Res. 2019 Feb;28(2):297-319. doi: 10.1007/s11136-018-1992-3. Epub 2018 Sep 17.
5
The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals.从 EQ-5D-3L 到 -5L 在 NICE 技术评估中的影响。
Pharmacoeconomics. 2019 Jan;37(1):75-84. doi: 10.1007/s40273-018-0701-y.
6
The Use of Health State Utility Values in Decision Models.健康状态效用值在决策模型中的应用。
Pharmacoeconomics. 2017 Dec;35(Suppl 1):77-88. doi: 10.1007/s40273-017-0550-0.
7
Cost-Effectiveness of Drug Treatments for Advanced Melanoma: A Systematic Literature Review.药物治疗晚期黑色素瘤的成本效益:系统文献回顾。
Pharmacoeconomics. 2017 Sep;35(9):879-893. doi: 10.1007/s40273-017-0517-1.
8
Comparative performance of the EQ-5D-5L and SF-6D index scores in adults with type 2 diabetes.2型糖尿病成人患者中EQ-5D-5L与SF-6D指数评分的比较表现
Qual Life Res. 2017 Aug;26(8):2057-2066. doi: 10.1007/s11136-017-1559-8. Epub 2017 Mar 31.
9
Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain.奥妥珠单抗联合苯丁酸氮芥用于西班牙慢性淋巴细胞白血病患者一线治疗的经济学评估
Clinicoecon Outcomes Res. 2016 Sep 21;8:475-484. doi: 10.2147/CEOR.S114524. eCollection 2016.
10
Cost-Effectiveness Analysis of Screening for and Managing Identified Hypertension for Cardiovascular Disease Prevention in Vietnam.越南心血管疾病预防中高血压筛查与管理的成本效益分析
PLoS One. 2016 May 18;11(5):e0155699. doi: 10.1371/journal.pone.0155699. eCollection 2016.